
rpact is an R package for planning, simulating, and
analyzing confirmatory clinical trials. It supports common tasks such as
sample size and power calculations for standard fixed-sample trials, as
well as classical group sequential designs with interim analyses.
Methods are available for continuous, binary, survival (time-to-event),
and count data endpoints.
For innovative trial designs, rpact provides
simulation-based evaluation of power and other operating
characteristics, multi-stage adaptive hypothesis tests based on the
combination testing principle, adaptive sample size or event-number
reassessment, multi-arm multi-stage (MAMS) designs, and population
enrichment designs. This allows users to start with routine trial
planning and use the same package for more advanced adaptive methods
when needed.
rpact covers the main steps of confirmatory trial
planning, simulation, and analysis:
getDataset(est = ..., se = ...)Install the latest stable release from CRAN:
install.packages("rpact")To try features that are not yet available in the CRAN release,
install the development version of rpact from GitHub:
# install.packages("pak")
pak::pak("rpact-com/rpact")Package information and tutorials are available at www.rpact.org. For function arguments, return values, and examples, see the function reference.
Step-by-step examples and tutorials are available in the
rpact vignettes at www.rpact.org/vignettes.
This deliberately simple example illustrates a basic sample size
calculation with rpact.
Suppose a study compares two treatments for high blood pressure. We expect the new treatment to lower systolic blood pressure by 15 mmHg on average, compared with 10 mmHg under standard treatment—a difference of 5 mmHg. We assume a standard deviation of 12 mmHg in each group. These numbers are illustrative assumptions, not recommendations for a clinical study.
How many participants are needed in two equally sized groups to detect this difference with 80% power?
library(rpact)
getSampleSizeMeans(
groups = 2, # Two treatment groups
alternative = 5, # Expected difference: 15 - 10 mmHg
stDev = 12, # Assumed standard deviation in each group
alpha = 0.05, # 5% significance level
beta = 0.20, # 80% power
sided = 2 # Two-sided test
) |>
summary()Sample size calculation for a continuous endpoint
Fixed sample analysis, two-sided significance level 5%, power 80%. The results were calculated for a two-sample t-test, H0: mu(1) - mu(2) = 0, H1: effect = 5, standard deviation = 12.
| Stage | Fixed |
|---|---|
| Stage level (two-sided) | 0.0500 |
| Efficacy boundary (z-value scale) | 1.960 |
| Lower efficacy boundary (t) | -3.503 |
| Upper efficacy boundary (t) | 3.503 |
| Number of subjects | 182.8 |
Legend:
This example uses a conventional two-sided test at the 5% significance level, without interim analyses. The calculated total sample size is approximately 183 participants. Rounding up to equally sized groups gives 92 participants per group, before allowing for missing data or dropouts. Power of 80% means an 80% chance of detecting the assumed difference if it truly exists under the planning assumptions.
We now make the study objective more explicit: we want to demonstrate
that the new treatment lowers blood pressure more than the
standard treatment. We therefore use a one-sided test
at the 2.5% significance level, a common choice for
confirmatory superiority trials. The direction of benefit is specified
before the study begins. Blood pressure reductions are recorded as
positive values, so alternative = 5 represents the expected
additional reduction with the new treatment.
We keep the same illustrative assumptions and 80% power, but add one interim analysis, when approximately half of the total statistical information is available. If the evidence is sufficiently strong, the study can stop early for efficacy. Otherwise, it continues to the final analysis.
Simply testing twice at the usual significance level would increase the chance of a false-positive conclusion. A group sequential design accounts for both analyses. Here, we use O’Brien–Fleming boundaries, which require particularly strong evidence to stop early.
getDesignGroupSequential(
kMax = 2, # One interim and one final analysis
informationRates = c(0.5, 1), # 50% information at interim, 100% at final
typeOfDesign = "OF", # O'Brien–Fleming boundaries
alpha = 0.025, # One-sided 2.5% significance level
beta = 0.20, # 80% power
sided = 1 # One-sided test
) |>
getSampleSizeMeans(
groups = 2, # Two treatment groups
alternative = 5, # Additional blood pressure reduction (mmHg)
stDev = 12 # Assumed standard deviation (mmHg)
) |>
summary()Sample size calculation for a continuous endpoint
Sequential analysis with a maximum of two looks (group sequential design), one-sided overall significance level 2.5%, power 80%. The results were calculated for a two-sample t-test, H0: mu(1) - mu(2) = 0, H1: effect = 5, standard deviation = 12.
| Stage | 1 | 2 |
|---|---|---|
| Planned information rate | 50% | 100% |
| Cumulative alpha spent | 0.0026 | 0.0250 |
| Stage levels (one-sided) | 0.0026 | 0.0240 |
| Efficacy boundary (z-value scale) | 2.797 | 1.977 |
| Efficacy boundary (t) | 7.169 | 3.520 |
| Cumulative power | 0.2096 | 0.8000 |
| Number of subjects | 92.1 | 184.2 |
| Expected number of subjects | 164.9 | |
| Stopping probability | 0.2096 | |
| Efficacy stopping probability by stage (under H0) | 0.0026 | |
| Efficacy stopping probability by stage | 0.2096 |
Legend:
The output shows the planned cumulative sample sizes and the efficacy boundaries at each analysis. Allowing an early stop usually requires a slightly larger maximum sample size than a corresponding study without interim analyses, but may reduce the number of participants actually needed.
This is an illustration of the workflow; a clinical study requires additional planning, including the timing and conduct of the interim analysis.
If you find a bug or would like to suggest an improvement, please use
the rpact GitHub issue tracker.
🐞 Report
a bug
Please include a minimal reproducible R example, or a runnable R
Markdown (.Rmd) or Quarto (.qmd)
document.
✨ Request
a feature
Please describe the use case, affected function(s), and the expected
benefit.
Before opening a new issue, please search existing issues to avoid duplicates.
Because GitHub issues are public, please do not include confidential, customer-specific, personal, regulated, or security-sensitive information.
RPACT Cloud is a web-based graphical user interface
for rpact. It provides guided, browser-based access to
selected rpact functionality, including study design,
sample size calculation, simulation, and reporting, without requiring
users to write R code.
RPACT Connect provides access to insights, downloads, and premium support for users and organizations working with RPACT software.
The RPACT User Group brings together users and
decision-makers from the pharmaceutical industry and CROs. Members meet
regularly to exchange experience, discuss best practices, and provide
input that helps shape the open-source development of
rpact.
We invite interested users and organizations to join the community, share know-how, and contribute to the future development of statistical tools for clinical trials.
For organizations using rpact in FDA/GxP-regulated
environments, RPACT offers support and formal validation documentation
for use on validated corporate computer systems. The documentation can
be customized and licensed for exclusive use by your company to support
applicable regulatory requirements.
The validation documentation also contains the personal access data
required to run the full test suite for installation qualification with
testPackage().
Contact RPACT to learn more.
rpact is free of charge and open source, licensed under LGPL-3. It implements a broad range of methods described in the monograph by Wassmer and Brannath (2025). Formal validation documentation is available to customers and supporting members through the RPACT service level agreement.
RPACT GmbH develops Statistical Tools for Drug Development. We develop and support R packages, Shiny applications, and cloud-based tools for clinical research, with services covering software development, validation, technical support, consulting, and training.
Our products include rpact and RPACT Cloud. We also maintain and support crmPack, the open-source package for dose escalation trial design, simulation, and analysis.
For more information, visit www.rpact.com.